The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028. Read this story
The first-quarter results come as Merck shows substantial progress in preparing for Keytruda's patent expiration in 2028. Read this story
More from CNBC | Business Biotechnology Biotech and Pharmaceuticals Pharmaceuticals Health care industry Merck & Co Inc Earnings FactSet Research Systems Inc Breaking news Pfizer Inc Moderna Inc Elanco Animal Health Inc business news cnbc Articles US: News Companies Business News Health & Science source:tagname:CNBC US Source